Humacyte Reports Positive Interim Results from Phase III Trial for Dialysis Access Vessel
During Humacyte's Q2 2026 earnings call, CEO Dr. Laura Niklason highlighted positive interim results from the company’s V012 Phase III trial of its ATEV (Acellular Tissue Engineered Vessel) in female dialysis patients. The vessel outperformed autologous fistula, which is currently considered standard care for vascular access. These findings were presented at the Vascular Annual Meeting in Boston and exceeded expectations set by Humacyte. The company also outlined its 2026 goals, including advancing Symvess commercialization, completing a pivotal trial of ATEV for dialysis access, filing a supplemental Biologics License Application (BLA) with the FDA, and initiating human trials for CTEV in coronary artery bypass grafting. Jim Mercadante, newly appointed Chief Commercial Officer, is leading efforts to scale Symvess commercialization. Dale Sander will provide financial results later during the call. The positive trial data could support regulatory submissions and potentially drive broader adoption of Humacyte’s engineered vessels.
Tickers: $HUMA
Topics: business update executive commentary financial results